Vanguard Group Inc Revance Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,733,699 shares of RVNC stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,733,699
Previous 5,994,459
4.35%
Holding current value
$14.7 Million
Previous $15.4 Million
4.35%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RVNC
# of Institutions
234Shares Held
82.8MCall Options Held
680KPut Options Held
896K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ4.16MShares$10.7 Million0.49% of portfolio
-
Alliancebernstein L.P. New York, NY3.26MShares$8.38 Million0.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...